| Mark P Bouchard, MD | |
|
5 Bucknam Rd, Suite 2c, Falmouth, ME 04105-1392 | |
| (207) 781-1500 | |
| (207) 781-1507 |
| Full Name | Mark P Bouchard |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 5 Bucknam Rd, Falmouth, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023040656 | NPI | - | NPPES |
| 254100099 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QS0010X | Family Medicine - Sports Medicine | MD14613 (Maine) | Secondary |
| 208M00000X | Hospitalist | MD14613 (Maine) | Secondary |
| 207Q00000X | Family Medicine | MD14613 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
| Maine Medical Partners | 9335043967 | 789 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467477349 PECOS PAC ID: 9335043967 Enrollment ID: O20031125000026 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639194509 PECOS PAC ID: 7517860588 Enrollment ID: O20040206000472 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598780447 PECOS PAC ID: 9335043967 Enrollment ID: O20040220000847 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134144090 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000191 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144245028 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000321 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073527388 PECOS PAC ID: 9335043967 Enrollment ID: O20050401000844 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark P Bouchard, MD 301c Us Route 1, Scarborough, ME 04074-9701 Ph: (207) 396-8600 | Mark P Bouchard, MD 5 Bucknam Rd, Suite 2c, Falmouth, ME 04105-1392 Ph: (207) 781-1500 |
News Archive
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.
People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
JoVE, the Journal of Visualized Experiments, will publish a procedure to identify newborns and children at-risk for developmental problems, especially those born prematurely.
› Verified 7 days ago
Catherine Krouse, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 6 Fundy Rd, Suite 400, Falmouth, ME 04105 Phone: 717-201-0711 | |
Dr. Charles Joseph De Sieyes, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 202 Us Route 1, Suite 200, Falmouth, ME 04105 Phone: 207-781-4488 Fax: 207-781-4470 | |
Regina Y Kim, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Gray Rd, Falmouth, ME 04105 Phone: 207-535-1340 Fax: 207-535-1358 | |
Dr. Adam Michael Kazimierczak, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Gray Rd, Falmouth, ME 04105 Phone: 207-535-1340 Fax: 207-535-1358 | |
Laura Blutstein, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 74 Gray Rd, Falmouth, ME 04105 Phone: 207-774-3070 Fax: 207-797-2267 | |
Dr. Kohar Dersimonian, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Bucknam Rd, Suite 2c, Falmouth, ME 04105 Phone: 207-781-1500 |